AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca has secured an exclusive global license for Zegfrovy, an oral EGFR inhibitor for lung cancer.
Asset / Drug
Drug and asset intelligence for Zegfrovy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
EGFR Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.